Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-023-02364-4.pdf
Reference24 articles.
1. Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312
2. Yoshino T, Komatsu Y, Yamada Y et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs 33:740–750
3. Yamaguchi K, Komatsu Y, Satoh T et al (2019) Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. Oncologist 24:e450-457
4. Saito Y, Takekuma Y, Komatsu Sugawara M (2022) Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment. Support Care Cancer doi: https://doi.org/10.1007/s00520-022-07381-z. Epub ahead of print. PMID: 36217043.
5. Wang Z, Xu J, Nie W et al (2014) Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 70:225–231
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical Outcome of Colorectal Cancer Patients with Concomitant Hypertension: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-05-14
2. Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment;Scientific Reports;2024-03-02
3. Updates in the management of cancer therapy-related hypertension;Current Opinion in Cardiology;2024-02-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3